For patients with symptomatic condition requiring therapy, ibrutinib is commonly advisable based on 4 period III randomized medical trials evaluating ibrutinib with chlorambucil monotherapy106 and other commonly utilized CIT combinations, particularly FCR, bendamustine plus rituximab and chlorambucil as well as obinutuzumab (ClbO).107–109 Ibrutin… Read More